Plenary Session 3:

Pricing policies and strategies are among the tools buyers and sellers use to achieve their goals, e.g., providing access to quality health products with high efficiency in utilizing finite resources or achieving business goals and generating revenue for growth and continued innovation and R&D.

Countries recognizing the need for more effective pricing policies to achieve affordable prices have been using collaborations to strengthen their buying powers, share key market information or use the power of collective negotiations.

There are a variety of initiatives across every WHO region on HTA, pricing procurement, and many public-private partnerships that have been attempting to reduce price-& affordability-related access barriers through cross-country multi-stakeholder collaborations.

The pharmaceutical industry recognizes the major differences in the abilities of countries to pay for their product and has been testing various market access and pricing strategies to make their products available earlier and at a more affordable price in low and middle-income countries.

Lessons learned from these initiatives must be considered to further identify sustainable and effective policies, collaborations and partnerships.

This roundtable will discuss potential future solutions for effective collaborations between countries and stakeholders toward pricing policies that can reduce inequities in access to essential health technologies in a sustainable manner.

Closing Ceremony:

The final day of the 2024 Fair Pricing Forum will start with a last set of parallel sessions on health technology assessments, intellectual property rights, and drug shortages. The Forum will end with a final plenary to discuss lessons learned and sustainable solutions towards fair pricing.

Session Material:

⬇️ PL3_session_slides_combined

⬇️ PL3_questions_answers_and_links